(HealthDay News) — Use of a polypill can potentially improve global cardiovascular health, according to research published in the Journal of the American College of Cardiology.

José M. Castellano, MD, PhD, from the Mount Sinai Medical Center in New York City, and colleagues reviewed the evidence from trials examining the efficacy and safety of polypills.

The researchers note that the results of these trials indicate that the polypill is viable for cardiovascular disease (CVD) prevention and management, although there is a lack of evidence for its effect on reducing CV events. 

Continue Reading

By reaching underdeveloped regions of the world, simplifying health care delivery, improving cost-effectiveness, increasing medication adherence and supporting a comprehensive prescription of cardioprotective drugs, the polypill has the potential to control the global health epidemic of CVD. 

Trials to examine the cost-effectiveness of reducing CV events with the polypill are currently underway.

“Available clinical data support the viability of the polypill in [CVD] prevention and management but with a few reservations,” the researchers wrote. 

“Further research of the polypill is needed, with the collective results having the potential power to change the face of health care across the world.”

One author disclosed financial ties to Ferrer Internacional, which manufactures a polypill.


  1. Castellano JM et al. J Am Coll Cardiol. 2014;64(6):613-621.